RA
RGNX icon

Royce & Associates’s Regenxbio RGNX Stock Holding History

Royce & Associates’s Portfolio RGNX Stock Details RGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-119,038
Closed -$1.71M – 802
2025
Q4 		$1.71M Buy
+119,038
New +$1.48M 0.02% 609
2023
Q4 		– Sell
-149,664
Closed -$2.46M – 926
2023
Q3 		$2.46M Sell
149,664
-16,250
-10% -$294K 0.03% 615
2023
Q2 		$3.32M Sell
165,914
-16,536
-9% -$319K 0.03% 582
2023
Q1 		$3.45M Buy
182,450
+100,871
+124% +$2.23M 0.03% 569
2022
Q4 		$1.85M Buy
81,579
+52,296
+179% +$1.18M 0.02% 658
2022
Q3 		$774K Buy
29,283
+12,761
+77% +$379K 0.01% 772
2022
Q2 		$408K Buy
+16,522
New +$413K ﹤0.01% 854
2020
Q3 		– Sell
-60,000
Closed -$2.21M – 1136
2020
Q2 		$2.21M Hold
60,000
– – 0.02% 648
2020
Q1 		$1.94M Hold
60,000
– – 0.03% 600
2019
Q4 		$2.46M Hold
60,000
– – 0.02% 659
2019
Q3 		$2.14M Hold
60,000
– – 0.02% 695
2019
Q2 		$3.08M Buy
60,000
+31,539
+111% +$1.57M 0.03% 614
2019
Q1 		$1.63M Buy
28,461
+88
+0.3% +$4.36K 0.01% 788
2018
Q4 		$1.19M Buy
28,373
+92
+0.3% +$5.4K 0.01% 837
2018
Q3 		$2.13M Sell
28,281
-11,933
-30% -$860K 0.01% 812
2018
Q2 		$2.88M Sell
40,214
-36,786
-48% -$1.76M 0.02% 748
2018
Q1 		$2.3M Buy
77,000
+18,000
+31% +$524K 0.02% 808
2017
Q4 		$1.96M Buy
+59,000
New +$1.78M 0.01% 854

Other funds holding RGNX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.53B AUM 154.61% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Royce & Associates's RGNX Position: Q1 2026 in Review

Royce & Associates sold out of Regenxbio (RGNX) in Q1 2026, closing a stake of 119,038 shares — an estimated $1.71M sold.

Royce & Associates first reported a position in RGNX in Q4 2017 and held it in 18 quarters. The position peaked at $3.45M in Q1 2023. 178 funds tracked by Wall St. Rank hold RGNX as of Q1 2026.

  • Royce & Associates reported no remaining Regenxbio position as of Q1 2026 after selling out during the quarter.
  • Royce & Associates sold 119,038 Regenxbio shares in Q1 2026, an estimated $1.71M.
  • Royce & Associates first reported a position in Regenxbio in Q4 2017 and held it in 18 quarters.
  • Royce & Associates's Regenxbio position peaked at $3.45M in Q1 2023.
  • 178 funds tracked by Wall St. Rank held Regenxbio as of Q1 2026.

Based on Royce & Associates's 13F filing for Q1 2026, filed 12 May 2026.